

COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide


Friday, March 12, 2021

DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Summary Information on Vaccine Products in Clinical Development

1 - Number of vaccines in clinical development 81


2 - Number of vaccines in pre-clinical development 182



3 - Candidates in clinical phase

Filter: Select phase of development (default is all)

Platform	Candidate vaccines (no. and %)
PS	Protein subunit 27 33%
WVnr	Viral Vector (non-replicating) 12 15%
DNA	DNA 11 14%
IV	Inactivated Virus 10 12%
RNA	RNA 10 12%
VVr	Viral Vector (replicating) 4 5%
VLP	Virus Like Particle 3 4%
VVr + APC	VVr + Antigen Presenting Cell 2 2%
LAV	Live Attenuated Virus 1 1%
WVnr + APC	WVnr + Antigen Presenting Cell 1 1%
81	



4 - Number of doses, schedule and route of administration of candidates in clinical phase

Number of doses & schedule	Candidate vaccines (no. and %)
1 dose	12 15%
Day 0	12
2 doses	50 62%
Day 0 + 14	6
Day 0 + 21	18
Day 0 + 28	26
3 doses	1 1%
Day 0 + 28 + 56	1
TBD / No Data (ND)	18 22%

Route of administration	Count	Percentage
Oral	2	2%
Injectable	68	84%
SC Sub cutaneous	2	2%
ID Intra dermal	3	4%
IM Intra muscular	63	78%
TBD / No Data (ND)	11	14%

